Skip to main content
. 2024 Apr 24;18(2):101347. doi: 10.1016/j.jcmgh.2024.04.004

Figure 2.

Figure 2

FOXL1+/PDGFRα+ double-positive telocytes are increased during the metaplasia development in the stomach. (A) Immunofluorescence staining of GSII (white), FOXL1 (red), PDGFRα (green), and DAPI (blue) in DMP-777 and L635-treated mouse stomach. In untreated mouse stomach, FOXL1+/PDGFRα+ double-positive telocytes were located near the isthmus. Following treatment with DMP-777 and L635, where metaplasia developed, there was an increase in the number of these telocytes. Also, telocytes spread throughout the gland, extending even to the base. Scale bar: 100 μm and 50 μm for enlarged. (B) Immunofluorescence staining of CD44v9 (white), FOXL1 (red), PDGFRα (green), and DAPI (blue). In the untreated stomach, FOXL1+/PDGFRα+ double-positive telocytes were located near the isthmus. In DMP-777 and L635-treated stomach, telocytes were also observed near the CD44v9-positive metaplastic cells at the base of the gland. Scale bar: 100 μm and 50 μm for enlarged. (C) Quantification of telocyte count. FOXL1+/PDGFRα+/DAPI+ telocyte count significantly increased in DMP-777 and L635-treated stomachs. Data presented as mean ± standard deviation (n = 5 for Untreated and n = 4 for DMP-777 and L635). ∗∗∗∗P < .0001. Dunnett multiple comparisons test; 1-way analysis of variance (F (2, 10) = 49.96; P < .0001).